Lorundrostat acts by directly inhibiting aldosterone synthesis while sparing other adrenal steroid pathways, potentially overcoming limitations of mineralocorticoid receptor antagonists such as ...

Lorundrostat, a selective aldosterone synthase inhibitor, significantly reduced systolic blood pressure in patients with ...

"Current therapeutic approaches targeting aldosterone, such as mineralocorticoid receptor ... production while sparing other adrenal steroid pathways, lorundrostat may offer better efficacy ...

Abbreviations: ACTH = adrenocorticotropic hormone; AME = apparent mineralocorticoid excess ... Monogenic forms of hypertension share a common pathway of increased reabsorption of sodium and ...

Per management, finerenone is the first drug targeting the mineralocorticoid receptor pathway which has shown cardiovascular benefits in a phase III study for treating HF with an LVEF of ≥40%.

In this study which investigated the diagnostic accuracy of confirmatory testing for primary aldosteronism, post-seated saline suppression test aldosterone concentrations overlapped between treatment ...

SGK1 is expressed at low levels in most cells but is stimulated under a variety of pathological conditions such as excess of glucocorticoid, mineralocorticoid ... mediate multiple intracellular ...

More recently, pharmacological agents targeting other neurohormonal pathways have demonstrated further opportunities ... 17 18 Spironolactone is a broad-spectrum mineralocorticoid blocker with side ...

Using a new approach to examine bacterial strain-sharing patterns, they discovered that stored drinking water is a key transmission pathway for E. coli bacteria within and between households in ...